Low mortality, stroke seen with newest Edwards TAVR system: study

March 15, 2015 5:51 PM

4 0

(Reuters) - Researchers on Sunday presented trial data showing very low mortality and stroke rates using the third generation version of Edwards Lifesciences Corp's non-invasive heart valve replacement system that could help support its U.S. approval.

Data compiled 30 days after the procedure showed a 2.2 percent mortality rate in high risk patients and a 1.1 percent death rate among intermediate risk patients whose diseased heart valves were replaced using the Edwards Sapien 3 transcatheter aortic valve replacement (TAVR) system.

Also read: China Growth Holds at 6.7%, Backed by Government and Consumers

Read more

To category page